دورية أكاديمية
أعرض في EDS

MPP(+)-induced toxicity in the presence of dopamine is mediated by COX-2 through oxidative stress.

التفاصيل البيبلوغرافية
العنوان: MPP(+)-induced toxicity in the presence of dopamine is mediated by COX-2 through oxidative stress.
المؤلفون: Hsieh YC; School of Medical Sciences, College of Life Sciences and Medicine, University of Aberdeen, Aberdeen, Scotland, UK., Mounsey RB, Teismann P
المصدر: Naunyn-Schmiedeberg's archives of pharmacology [Naunyn Schmiedebergs Arch Pharmacol] 2011 Aug; Vol. 384 (2), pp. 157-67. Date of Electronic Publication: 2011 Jun 12.
نوع المنشور: Journal Article; Research Support, Non-U.S. Gov't
اللغة: English
بيانات الدورية: Publisher: Springer Verlag Country of Publication: Germany NLM ID: 0326264 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1432-1912 (Electronic) Linking ISSN: 00281298 NLM ISO Abbreviation: Naunyn Schmiedebergs Arch Pharmacol Subsets: MEDLINE
أسماء مطبوعة: Original Publication: Berlin, New York, Springer Verlag.
مواضيع طبية MeSH: 1-Methyl-4-phenylpyridinium/*toxicity , Cyclooxygenase 2/*metabolism , Dopamine/*metabolism , Dopaminergic Neurons/*drug effects , Oxidative Stress/*drug effects, Animals ; Apoptosis/drug effects ; Cell Survival/drug effects ; Cells, Cultured ; Cyclooxygenase 2 Inhibitors/pharmacology ; Dopamine/pharmacology ; Dopaminergic Neurons/enzymology ; Dopaminergic Neurons/metabolism ; Immunohistochemistry ; Mesencephalon/cytology ; Mesencephalon/embryology ; Mesencephalon/metabolism ; Parkinson Disease/enzymology ; Parkinson Disease/metabolism ; Parkinson Disease/pathology ; Rats ; Rats, Sprague-Dawley ; Reactive Oxygen Species/metabolism
مستخلص: Accumulating evidence suggests that endogenous dopamine may act as a neurotoxin and thereby participate in the pathophysiology of Parkinson's disease (PD). Cyclooxygenase-2 (COX-2) has been implicated in the pathogenesis of PD due to its ability to generate reactive oxygen species (ROS). Inhibition of COX-2 leads to neuroprotection by preventing the formation of dopamine-quinone. In this study, we examined whether dopamine mediates 1-methyl-4-phenylpyridinium (MPP(+))-induced toxicity in primary ventral mesencephalic (VM) neurons, an in vitro model of PD, and if so, whether the protective effects of COX-2 inhibitors on dopamine mediated MPP(+)-induced VM neurotoxicity and VM dopaminergic cell apoptosis result from the reduction of ROS. Reserpine, a dopamine-depleting agent, significantly reduced VM neurotoxicity induced by MPP(+), whereas dopamine had an additive effect on MPP(+)-induced VM neurotoxicity and VM dopaminergic cell apoptosis. However, inhibition of COX-2 by a selective COX-2 inhibitor (DFU) or ibuprofen significantly attenuated MPP(+)-induced VM cell toxicity and VM dopaminergic cell apoptosis, which was accompanied by a decrease in ROS production in VM dopaminergic neurons. These results suggest that dopamine itself mediates MPP(+)-induced VM neurotoxicity and VM dopaminergic cell apoptosis in the presence of COX-2.
References: BMJ. 1996 Mar 16;312(7032):703-4; author reply 704-5. (PMID: 8597749)
Neuroreport. 1994 Apr 14;5(8):1009-11. (PMID: 8061280)
EMBO J. 1995 Feb 15;14(4):736-42. (PMID: 7882977)
Ann Neurol. 2003;53 Suppl 3:S26-36; discussion S36-8. (PMID: 12666096)
J Neurosci. 2005 Nov 2;25(44):10180-7. (PMID: 16267225)
Mov Disord. 1986;1(1):65-8. (PMID: 3504233)
J Neurochem. 1995 Feb;64(2):825-32. (PMID: 7830076)
J Neurosci. 2007 Mar 21;27(12):3338-46. (PMID: 17376994)
Neurochem Int. 2007 Jun;50(7-8):905-15. (PMID: 17084486)
Ann N Y Acad Sci. 2003 Jun;991:272-7. (PMID: 12846993)
Br J Dermatol. 2006 Jun;154(6):1071-9. (PMID: 16704636)
J Biol Chem. 1998 Feb 6;273(6):3756-64. (PMID: 9452508)
Methods Mol Med. 2003;79:387-95. (PMID: 12506711)
Neurosci Lett. 2002 Sep 6;329(3):354-8. (PMID: 12183047)
Adv Exp Med Biol. 2001;500:373-96. (PMID: 11764972)
Anat Rec. 1991 Dec;231(4):482-97. (PMID: 1793176)
Pharmacol Ther. 1991;49(3):153-79. (PMID: 1905023)
J Cell Biol. 2004 May 10;165(3):335-46. (PMID: 15123735)
Neuroreport. 1998 Aug 3;9(11):2569-72. (PMID: 9721934)
Adv Exp Med Biol. 1998;446:203-22. (PMID: 10079845)
FEBS Lett. 1985 Jul 8;186(2):224-8. (PMID: 3874094)
Nat Med. 2002 Jun;8(6):600-6. (PMID: 12042811)
Nat Med. 2004 Jul;10 Suppl:S18-25. (PMID: 15298006)
Proc Natl Acad Sci U S A. 1996 Mar 5;93(5):1956-61. (PMID: 8700866)
J Neurochem. 1995 Feb;64(2):919-24. (PMID: 7830086)
J Neurochem. 1999 Sep;73(3):1329-32. (PMID: 10461928)
Proc Natl Acad Sci U S A. 2003 Apr 29;100(9):5473-8. (PMID: 12702778)
Annu Rev Biochem. 2000;69:145-82. (PMID: 10966456)
Neuropsychopharmacology. 2003 Sep;28(9):1579-88. (PMID: 12784118)
J Neurosci. 2005 Oct 12;25(41):9428-33. (PMID: 16221852)
Br J Pharmacol. 1997 May;121(1):105-17. (PMID: 9146894)
J Neurochem. 1998 Oct;71(4):1635-42. (PMID: 9751197)
FASEB J. 2005 Jul;19(9):1134-6. (PMID: 15845609)
Neuroscience. 2000;101(1):67-76. (PMID: 11068137)
Prog Neurobiol. 2001 Oct;65(2):135-72. (PMID: 11403877)
Br J Pharmacol. 1988 Oct;95(2):449-58. (PMID: 3265882)
Crit Rev Neurobiol. 1999;13(1):45-82. (PMID: 10223523)
Mov Disord. 1997 May;12(3):453-6. (PMID: 9159748)
Neuroscience. 1994 Jun;60(3):809-23. (PMID: 7936201)
معلومات مُعتمدة: United Kingdom WT_ Wellcome Trust
المشرفين على المادة: 0 (Cyclooxygenase 2 Inhibitors)
0 (Reactive Oxygen Species)
EC 1.14.99.1 (Cyclooxygenase 2)
R865A5OY8J (1-Methyl-4-phenylpyridinium)
VTD58H1Z2X (Dopamine)
تواريخ الأحداث: Date Created: 20110614 Date Completed: 20111212 Latest Revision: 20211020
رمز التحديث: 20231215
مُعرف محوري في PubMed: PMC3145900
DOI: 10.1007/s00210-011-0660-8
PMID: 21667279
قاعدة البيانات: MEDLINE
الوصف
تدمد:1432-1912
DOI:10.1007/s00210-011-0660-8